Please use this identifier to cite or link to this item:
|Title:||Solid cancer: Evaluating potential efficacy of epigenetic drugs||Authors:||Ku, C.-S.||Issue Date:||Apr-2012||Citation:||Ku, C.-S. (2012-04). Solid cancer: Evaluating potential efficacy of epigenetic drugs. Gastric and Breast Cancer 11 (2) : 102-107. ScholarBank@NUS Repository. https://doi.org/10.2122/gbc.2012.0213||Abstract:||Current generation of targeted cancer drugs in the treatment of solid cancers, with the exceptions of trastuzumab and vemurafenib, resistance and disease progression limit the effectiveness of most signal transduction inhibitors available. Epigenomic drugs and microRNAs-based agents represent one of promising categories in clinical development to increase tumor cells sensitivity to combined therapeutics. Here, I discuss latest data and perspectives in overcoming current therapy resistance by treating solid tumors.||Source Title:||Gastric and Breast Cancer||URI:||http://scholarbank.nus.edu.sg/handle/10635/116891||ISSN:||11097655||DOI:||10.2122/gbc.2012.0213|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jul 9, 2019
checked on May 22, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.